DiscGenics Revenue and Competitors
Estimated Revenue & Valuation
- DiscGenics's estimated annual revenue is currently $4M per year.
- DiscGenics's estimated revenue per employee is $77,500
- DiscGenics's total funding is $68M.
Employee Data
- DiscGenics has 52 Employees.
- DiscGenics grew their employee count by -12% last year.
DiscGenics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO & Chairman the Board | Reveal Email/Phone |
2 | Senior Director Clinical & Regulatory Affairs | Reveal Email/Phone |
3 | Chief Operating Officer & Chief Commercialization Officer | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | Director | Reveal Email/Phone |
6 | Sr. Director Operations | Reveal Email/Phone |
7 | Sr. Director, QA / QC (Site Head Quality) | Reveal Email/Phone |
8 | Director Manufacturing | Reveal Email/Phone |
9 | Manager, Operations & Finance | Reveal Email/Phone |
10 | Global Supply Chain Manager | Reveal Email/Phone |
DiscGenics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8945.7M | 23666 | 5% | N/A | N/A |
What Is DiscGenics?
DiscGenics is a privately held, clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions of patients suffering from the debilitating effects of back pain. DiscGenicsￃﾢ￢ﾂﾬ￢ﾄﾢ first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with mild to moderate degenerative disc disease.
keywords:N/A
$68M
Total Funding
52
Number of Employees
$4M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
DiscGenics News
Positive interim data that highlighted the safety and efficacy of DiscGenics' cell therapy for degenerative disc disease was the most-read...
SALT LAKE CITY, Sept. 9, 2020 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has appointed former Medtroni ...
DiscGenics, Inc., a Salt Lake City, UT-based clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, raised $50m in Series C funding. The round was led by Ci:z Investment ...
SALT LAKE CITY, Aug. 25, 2020 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has raised $50 million in a Ser ...
Other Companies in Salt Lake City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.6M | 52 | 16% | N/A |
#2 | $11.7M | 52 | 13% | N/A |
#3 | $11.5M | 52 | -22% | N/A |
#4 | $15M | 52 | 2% | N/A |
#5 | $11.5M | 52 | -5% | N/A |